Identification of a novel HRAS variant and its association with papillary thyroid carcinoma

  • Authors:
    • Rui Dou
    • Lili Zhang
    • Tingxia Lu
    • Dong Liu
    • Fang Mei
    • Jian Huang
    • Linxue Qian
  • View Affiliations

  • Published online on: January 17, 2018     https://doi.org/10.3892/ol.2018.7818
  • Pages:4511-4516
Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

HRas proto‑oncogene (HRAS) is one of the most commonly mutated genes in thyroid cancer, with mutations frequently occurring in the follicular and Hurthle cell subtypes. However, the contribution of mutations in HRAS to papillary thyroid carcinoma (PTC) progression and the tall‑cell variant (TCV) is poorly understood. The aim of the present study was to investigate the somatic genetic variants present in HRAS in patients with PTC, and to investigate the association of these mutations with PTC. The present study is a retrospective case‑control study using tumor samples collected from 139 patients with PTC and blood samples from 195 healthy individuals. All patient samples were screened for mutations in ‘hotspot’ regions of HRAS and B‑raf proto‑oncogene (BRAF) by single‑stranded conformational polymorphism analysis, followed by direct sequencing. A novel variant (IVS1‑82del gctgggcctggg) in the HRAS 5'‑untranslated region was identified. There was no difference in age or sex of patients with PTC and the healthy controls; however, the HRAS variant was more frequently detected in PTC tissue than in the healthy control samples (37 vs. 26%, P=0.04). There was no association between the HRAS variant and age, sex, tumor size, encapsulation, multifocality/intra‑thyroidal spread, Tumor‑Node‑Metastasis stage, history of Hashimoto's disease, BRAF V600E mutation or PTC subtype (all P>0.05). There were differences of BRAF V600E distribution among different subtypes (χ2=6.390, P=0.041). HRAS variant co‑occurring with the BRAF V600E mutation accounted for 31.6% of the total number (P=0.196). Therefore, this novel variant of HRAS (IVS1‑82del gctgggcctggg) may be associated with PTC; however, larger scale studies are required to assess the contribution of this novel HRAS variant to PTC progression.

Related Articles

Journal Cover

April 2018
Volume 15 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

2016 Impact Factor: 1.39
Ranked #68/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Dou, R., Zhang, L., Lu, T., Liu, D., Mei, F., Huang, J., & Qian, L. (2018). Identification of a novel HRAS variant and its association with papillary thyroid carcinoma. Oncology Letters, 15, 4511-4516. https://doi.org/10.3892/ol.2018.7818
MLA
Dou, R., Zhang, L., Lu, T., Liu, D., Mei, F., Huang, J., Qian, L."Identification of a novel HRAS variant and its association with papillary thyroid carcinoma". Oncology Letters 15.4 (2018): 4511-4516.
Chicago
Dou, R., Zhang, L., Lu, T., Liu, D., Mei, F., Huang, J., Qian, L."Identification of a novel HRAS variant and its association with papillary thyroid carcinoma". Oncology Letters 15, no. 4 (2018): 4511-4516. https://doi.org/10.3892/ol.2018.7818